Heartflow, Inc. (HTFL)
Nasdaq: HTFL · Surgical & Medical Instruments & Apparatus · Mountain View, CA · filing with the SEC since 2009
Who owns Heartflow, Inc.
As filed with the SECHolders of 5% or more
4
BCLS Fund III Investments, LP holds 9.8% of Common Stock, $0.001 par value per share, as its SCHEDULE 13G/A filed Aug 14, 2026 says.
Directors and officers
11
report now, of 12 people on the record since 2025. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 4 named at left.
Holders of 5% or moreshare of the class, as filed
BCLS Fund III Investments, LP
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, $0.001 par value per share · 12.2% in May 15, 2026
Wellington Management Group LLP
SCHEDULE 13G/A · filed Aug 13, 2026 · Common Stock · 10.7% in Aug 6, 2026
Blackrock, Inc.
SCHEDULE 13G · filed Jul 28, 2026 · Common Stock
Fmr LLC
SCHEDULE 13G · filed Nov 5, 2025 · COMMON STOCK
HealthCor Partners Management LP
SCHEDULE 13G · filed Mar 31, 2026 · COMMON STOCK · reported falling below 5%, from 7.9% in Nov 24, 2025
Hayfin Management Holdings Limited
SCHEDULE 13G/A · filed May 11, 2026 · Class A Common Stock, $0.001 par value · reported falling below 5%, from 6.2% in Nov 14, 2025
What HTFL reports owning in othersstakes of 5% or more, and other ties
2 subsidiaries in 2 countries, from the list filed with the 10-K filed Mar 18, 2026.
Insider tradesForm 4
35sales
1purchases
35sales on a scheduled plan
4people selling
$28.7Msold, in dollars
$1.1Mbought, in dollars
Open-market trades on Form 4 from Nov 10, 2025 to Nov 10, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 10, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window7 of 23 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Bain Capital Life Sciences III General Partner, LLC | 10% owner | 4 | $58.9M | 0 | 0 | $0 |
| Bain Capital Life Sciences Investors, LLC | 10% owner | 1 | $56.1M | 0 | 0 | $0 |
| Farquhar John C.M. | Chief Executive Officer | 16 | $15.0M | 16 | 0 | $0 |
| Rogers Campbell | Chief Medical Officer | 8 | $8.0M | 8 | 0 | $0 |
| Verghese Vikram | Chief Financial Officer | 9 | $5.2M | 9 | 0 | $0 |
| Cullivan Julie A | director | 2 | $400,000 | 2 | 0 | $0 |
| Lightcap Jeffrey C | director | 0 | $0 | 0 | 1 | $1.1M |